Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
The closing price of Cabaletta Bio Inc (NASDAQ: CABA) was $1.29 for the day, up 8.40% from the previous closing price of $1.19. In other words, the price has increased by $8.40 from its previous closing price. On the day, 0.89 million shares were traded.
Ratios:
Our analysis of CABA’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 6.15 and its Current Ratio is at 6.15. In the meantime, Its Debt-to-Equity ratio is 0.10 whereas as Long-Term Debt/Eq ratio is at 0.04.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Evercore ISI on December 20, 2024, Downgraded its rating to In-line and sets its target price to $6 from $15 previously.
On December 19, 2024, Wells Fargo Downgraded its rating to Equal Weight which previously was Overweight and also lowered its target price recommendation from $12 to $6.
On October 10, 2024, UBS started tracking the stock assigning a Buy rating and target price of $10.UBS initiated its Buy rating on October 10, 2024, with a $10 target price.
Stock Price History:
Over the past 52 weeks, CABA has reached a high of $13.50, while it has fallen to a 52-week low of $0.99. The 50-Day Moving Average of the stock is -9.44%, while the 200-Day Moving Average is calculated to be -59.03%.
Shares Statistics:
A total of 50.74M shares are outstanding, with a floating share count of 46.16M. Insiders hold about 9.03% of the company’s shares, while institutions hold 70.99% stake in the company.
Earnings Estimates
Investors are keenly observing as 6.0 analysts analyze and rate the current performance of Cabaletta Bio Inc (CABA) in the stock market.The consensus estimate for the next quarter is -$0.59, with high estimates of -$0.08 and low estimates of -$0.73.
Analysts are recommending an EPS of between -$1.22 and -$2.88 for the fiscal current year, implying an average EPS of -$2.29. EPS for the following year is -$2.19, with 7.0 analysts recommending between -$0.85 and -$3.17.
